Education
About Us
Working with TipRanks
Follow Us
HLS Therapeutics Inc (TSE:HLS)
TSX:HLS
HLS Stock Chart & Stats
C$4.56
C$0.04(1.06%)
At close: 4:00 PM EST
C$4.56
C$0.04(1.06%)
Day’s Range― - ―
52-Week RangeC$3.90 - C$5.77
Previous CloseN/A
Volume4.75K
Average Volume (3M)19.90K
Market Cap
C$142.61M
Enterprise ValueC$211.13M
Total Cash (Recent Filing)C$10.78M
Total Debt (Recent Filing)C$54.09M
Price to Earnings (P/E)―
Beta0.82
Next Earnings
Mar 12, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding31,273,682
10 Day Avg. Volume21,807
30 Day Avg. Volume19,898
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)1.22
Price to Sales (P/S)1.54
P/FCF Ratio10.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$7.25Price Target Upside58.99% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Analyst SentimentAnalyst maintains an Outperform rating and raises the price target on HLS, signaling stronger analyst conviction that can attract investor interest.
Regulatory ApprovalHealth Canada approval of NILEMDO enables a Canadian launch with eight years of data protection, supporting a new revenue stream for the company.
Revenue Potential From Product LaunchesPlanned launches of Nexletol and NEXLIZET carry the potential to substantially expand sales and more than double current revenue if market uptake matches forecasts.
Bears Say
Approval Timing RiskRegulatory requests for extra information are likely to add months to the approval timeline for NEXLIZET, delaying commercialization and expected revenue contribution.
Manufacturing And Compliance CostsHeightened scrutiny of manufacturing processes and biopharmaceutics raises the likelihood of further compliance demands and increased development costs.
Regulatory Non-complianceNotice of Non-compliance for NEXLIZET requires additional chemistry and manufacturing data, creating a regulatory hurdle that must be addressed before approval.
HLS Therapeutics Inc News
HLS FAQ
What was HLS Therapeutics Inc’s price range in the past 12 months?
HLS Therapeutics Inc lowest stock price was C$3.90 and its highest was C$5.76 in the past 12 months.
What is HLS Therapeutics Inc’s market cap?
HLS Therapeutics Inc’s market cap is C$142.61M.
When is HLS Therapeutics Inc’s upcoming earnings report date?
HLS Therapeutics Inc’s upcoming earnings report date is Mar 12, 2026 which is in 55 days.
How were HLS Therapeutics Inc’s earnings last quarter?
HLS Therapeutics Inc released its earnings results on Nov 13, 2025. The company reported -C$0.167 earnings per share for the quarter, missing the consensus estimate of -C$0.086 by -C$0.081.
Is HLS Therapeutics Inc overvalued?
According to Wall Street analysts HLS Therapeutics Inc’s price is currently Undervalued.
Does HLS Therapeutics Inc pay dividends?
HLS Therapeutics Inc pays a Quarterly dividend of C$0.05 which represents an annual dividend yield of N/A. See more information on HLS Therapeutics Inc dividends here
What is HLS Therapeutics Inc’s EPS estimate?
HLS Therapeutics Inc’s EPS estimate is -0.04.
How many shares outstanding does HLS Therapeutics Inc have?
HLS Therapeutics Inc has 31,273,682 shares outstanding.
What happened to HLS Therapeutics Inc’s price movement after its last earnings report?
HLS Therapeutics Inc reported an EPS of -C$0.167 in its last earnings report, missing expectations of -C$0.086. Following the earnings report the stock price went down -7.588%.
Which hedge fund is a major shareholder of HLS Therapeutics Inc?
Currently, no hedge funds are holding shares in TSE:HLS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
HLS Therapeutics Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$7.25 (58.99% Upside)
C$7.25 (58.99% Upside)
Blogger Sentiment
Bullish
TSE:HLS Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.77%
12-Months-Change
Fundamentals
Return on Equity
-20.49%
Trailing 12-Months
Asset Growth
-22.30%
Trailing 12-Months
Company Description
HLS Therapeutics Inc
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also offers MyCare psychiatry lab assays and MyCare Insite point of care therapeutic drug-level monitoring tests. In addition, the company holds the U.S. marketing rights of Absorica, a commercial stage dermatology product; Canadian rights of Trinomia for CV therapeutics; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. was founded in 2018 and is headquartered in Etobicoke, Canada.
HLS Stock 12 Month Forecast
Average Price Target
C$7.25
▲(58.99% Upside)
Technical Analysis
Knight Therapeutics
―
Cipher Pharmaceuticals
―
Aequus Pharmaceuticals
―
Medexus Pharmaceuticals Inc
―
Biosyent
―
Options Prices
Currently, No data available
---